EUVIMEDEUVIMED entdecken
Crossref

Design, Synthesis, and Evaluation of Novel Phenoselenazine Derivatives as Potent Modulators of Aβ42 Aggregation

Ahmed A Hefny, Rahul C Karuturi, Chandra Mouli R Madhuranthakam iD, Praveen P N Rao iD

Journal of Medicinal Chemistry · 13.08.2026 · 69 (15) · 19482-19501

DOI: 10.1021/acs.jmedchem.6c01959 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 27.07.2026. Verfasst von Ahmed A Hefny und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Health Sciences Campus, University of Waterloo, 200 University Avenue West, Waterloo, OntarioN2L 3G1, Canada. Hauptthemen laut MEDLINE: Amyloid beta-Peptides, Drug Design, Organoselenium Compounds, Antioxidants. Die Arbeit nennt 77 Literaturangaben. Gefördert von: Ontario Research Foundation, Egyptian Cultural and Educational Bureau, Abu Dhabi University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A novel class of fused tricyclic phenoselenazine derivatives possessing a redox-active selenium atom were designed, synthesized, and evaluated as Aβ42 aggregation inhibitors with antioxidant activity. They exhibit remarkable inhibition of Aβ42 aggregation as confirmed by fluorescence aggregation kinetics study, electron microscopy, and cell-based studies in mouse hippocampal HT22 neuronal and BV2 microglial cells. Compounds 5i and 9g exhibited potent inhibition of Aβ42 aggregation with IC50 values of 350 and 317 nM, respectively, with compound 9g exhibiting exceptional ability to destabilize preformed Aβ42 fibrils (IC50 = 210 nM), surpassing those of the reference compounds resveratrol and methylene blue. Both 5i and 9g showed efficient blood–brain barrier permeability and provided significant neuroprotection toward Aβ42-induced cytotoxicity and demonstrated strong antioxidant properties by conferring protection toward hydrogen peroxide-induced cytotoxicity in mouse hippocampal HT22 cells. Collectively, our results demonstrate that these novel phenoselenazines represent a promising class of therapeutics to treat Alzheimer’s disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyloid beta-PeptidesDrug DesignOrganoselenium CompoundsAntioxidantsPeptide FragmentsNeuroprotective AgentsProtein AggregatesAnimalsMiceStructure-Activity RelationshipCell LineHippocampusBlood-Brain Barrier

Substanzen

Amyloid beta-PeptidesOrganoselenium CompoundsAntioxidantsamyloid beta-protein (1-42)Peptide FragmentsNeuroprotective AgentsProtein Aggregates

Autor:innen und Institutionen

  • School of Pharmacy, Health Sciences Campus, University of Waterloo, 200 University Avenue West, Waterloo, OntarioN2L 3G1, Canada.
  • Medicinal Chemistry Department, Faculty of Pharmacy, Beni-Suef University, Beni-Suef62514, Egypt.
  • Chemical Engineering Department, Abu Dhabi University, Abu Dhabi, United Arab Emirates.

ORCID-Profile: Chandra Mouli R Madhuranthakam, Praveen P N Rao

Förderung

  • Ontario Research Foundation
  • Egyptian Cultural and Educational Bureau
  • Abu Dhabi University
  • Natural Sciences and Engineering Research Council of Canada
  • Canada Foundation for Innovation
  • Ministry of Higher Education and Scientific Research
  • Ontario Ministry of Research and Innovation
  • Ministry of Colleges and Universities

Zitieren

APA

Hefny, A. A., Karuturi, R. C., Madhuranthakam, C. M. R., & Rao, P. P. N. (2026). Design, Synthesis, and Evaluation of Novel Phenoselenazine Derivatives as Potent Modulators of Aβ42 Aggregation. Journal of Medicinal Chemistry, 69(15), 19482-19501. https://doi.org/10.1021/acs.jmedchem.6c01959

Vancouver

Hefny AA, Karuturi RC, Madhuranthakam CMR, Rao PPN. Design, Synthesis, and Evaluation of Novel Phenoselenazine Derivatives as Potent Modulators of Aβ42 Aggregation. Journal of Medicinal Chemistry. 2026;69(15):19482-19501. doi:10.1021/acs.jmedchem.6c01959

BibTeX
@article{Hefny2026,
  author = {Hefny, Ahmed A and Karuturi, Rahul C and Madhuranthakam, Chandra Mouli R and Rao, Praveen P N},
  title = {Design, Synthesis, and Evaluation of Novel Phenoselenazine Derivatives as Potent Modulators of Aβ42 Aggregation},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  volume = {69},
  number = {15},
  pages = {19482--19501},
  doi = {10.1021/acs.jmedchem.6c01959}
}
Kostenlos starten →